Dark | Light
# Zentalis Pharmaceuticals, LLC (ZNTL)

ZNTL stock shows positive momentum following strong Phase [--] data for ZN-c3, but faces scrutiny over regulatory and manufacturing challenges.

### About Zentalis Pharmaceuticals, LLC
Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies.  
Zentalis Pharmaceuticals, LLC uses the ticker $ZNTL for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- Zentalis Pharmaceuticals, LLC (ZNTL) social dominance is up 80.95% from the previous week.

### Price: $2.40
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/close.tsv)  
The stock price has seen a recent upward trend, likely driven by positive Phase [--] data for ZN-c3, indicating investor optimism. However, concerns about regulatory approval timelines and manufacturing scale-up may be limiting more substantial gains.  

24-Hour: -2.93%
7-Day: -1%
30-Day: -17.77%

1-Year High: $3.70 on 2026-01-09  
1-Year Low: $1.20 on 2025-06-30  
  
  
### AltRank: [-----]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/alt_rank.tsv)  
Zentalis Pharmaceuticals, LLC (ZNTL) is currently AltRank #1,529 based on combined combined social and market metrics
Daily Average: [-----]  
[--] Week: [-----] [----]  
1-Year High: [-----] on 2026-01-28  
1-Year Low: [---] on 2026-01-25  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] [---]  
1-Year High: [--] on 2026-02-03  
1-Year Low: [--] on 2026-02-05  
  
  
### Engagements: [---] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/interactions.tsv)  
Current Value: [---]  
Daily Average: [-----]  
[--] Week: [-----] -22%  
[--] Month: [------] -81%  
[--] Months: [-------] +32%  
[--] Year: [-------] -62%  
1-Year High: [------] on 2026-01-12  
1-Year Low: [--] on 2025-09-07  

Engagements by network (24h):
TikTok: [--]
X: [---]
Reddit: [--]
YouTube: [--]

  
  
### Mentions: [--] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/posts_active.tsv)  
Current Value: [--]  
Daily Average: [--]  
[--] Week: [---] -43%  
1-Year High: [---] on 2026-01-11  
1-Year Low: [--] on 2025-12-07  

Mentions by network (24h):
TikTok: [--]
X: [--]
Reddit: [--]
YouTube: [--]

  
  
### Creators: [--] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/contributors_active.tsv)  
[--] unique social accounts have posts mentioning Zentalis Pharmaceuticals, LLC (ZNTL) in the last [--] hours which is up 50% from [--] in the previous [--] hours
Daily Average: [--]  
[--] Week: [--] -33%  
1-Year High: [---] on 2026-01-10  
1-Year Low: [--] on 2025-12-07  
  
  
### Sentiment: 100%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/sentiment.tsv)  
Current Value: 100%  
Daily Average: 89%  
[--] Week: 100% no change  
[--] Month: 100% +10%  
[--] Months: 100% no change  
[--] Year: 100% no change  
1-Year High: 100% on 2025-02-19  
1-Year Low: 33% on 2025-05-29  

Most Supportive Themes:
- Zentalis Pharmaceuticals Announces Positive Phase [--] Data for ZN-c3: (70%) Zentalis Pharmaceuticals LLC presented encouraging Phase [--] clinical trial results for their drug candidate ZN-c3, showing significant efficacy in treating certain types of cancer. The data has been met with enthusiasm from the oncology community and investors.
- Zentalis Expands Clinical Trial Pipeline with New Cancer Targets: (30%) The company is broadening its research and development efforts, initiating new clinical trials for ZN-c3 and other promising compounds targeting various advanced cancers. This expansion signals a commitment to addressing unmet medical needs.
  
Most Critical Themes:
- Regulatory Hurdles and Competition in Oncology Drug Development: (60%) Zentalis Pharmaceuticals faces a competitive landscape and stringent regulatory pathways for new cancer therapies. The success of ZN-c3 will depend on navigating these challenges effectively and demonstrating a clear advantage over existing treatments.
- Manufacturing Scale-Up and Supply Chain Considerations for ZN-c3: (40%) Ensuring a robust and scalable manufacturing process for ZN-c3 is crucial for its eventual market availability. Potential supply chain disruptions or manufacturing complexities could impact the drug's timely delivery to patients.
  
  
  
### Social Dominance: 0.00184%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/social_dominance.tsv)  
Current Value: 0.00184%  
Daily Average: 0.00465%  
[--] Week: 0.0038% +0.0017%  
[--] Month: 0.007% -0.003%  
[--] Months: 0.007% +0.0048%  
[--] Year: 0.007% -0.0005999999999999998%  
1-Year High: 0.061% on 2026-01-11  
1-Year Low: 0.0002% on 2025-10-04  
  
  
### Market Dominance: 0.0001733849341875062%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/market_dominance.tsv)  
Current Value: 0.0001733849341875062%  
Daily Average: 0%  
1-Year High: 0.00726% on 2026-01-13  
1-Year Low: 0.00017% on 2026-02-18  
  
  
### Market Cap: $152,811,838
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:zentalis-pharmaceuticals-llc/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/zentalis-pharmaceuticals-llc/time-series/market_cap.tsv)  
Current Value: $152,811,838  
Daily Average: $173,392,086  
[--] Week: $150,221,807 -5.70%  
[--] Month: $152,811,838 -20%  
1-Year High: $227,275,234 on 2026-01-14  
1-Year Low: $143,099,222 on 2026-02-05

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing

Zentalis Pharmaceuticals, LLC (ZNTL)

ZNTL stock shows positive momentum following strong Phase [--] data for ZN-c3, but faces scrutiny over regulatory and manufacturing challenges.

About Zentalis Pharmaceuticals, LLC

Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies.
Zentalis Pharmaceuticals, LLC uses the ticker $ZNTL for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

  • Zentalis Pharmaceuticals, LLC (ZNTL) social dominance is up 80.95% from the previous week.

Price: $2.40

Price Line Chart
Price 24-Hour Time-Series Raw Data
The stock price has seen a recent upward trend, likely driven by positive Phase [--] data for ZN-c3, indicating investor optimism. However, concerns about regulatory approval timelines and manufacturing scale-up may be limiting more substantial gains.

24-Hour: -2.93% 7-Day: -1% 30-Day: -17.77%

1-Year High: $3.70 on 2026-01-09
1-Year Low: $1.20 on 2025-06-30

AltRank: [-----]

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Zentalis Pharmaceuticals, LLC (ZNTL) is currently AltRank #1,529 based on combined combined social and market metrics Daily Average: [-----]
[--] Week: [-----] [----]
1-Year High: [-----] on 2026-01-28
1-Year Low: [---] on 2026-01-25

Galaxy Score: [-----]

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
1-Year High: [--] on 2026-02-03
1-Year Low: [--] on 2026-02-05

Engagements: [---] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [-----]
[--] Week: [-----] -22%
[--] Month: [------] -81%
[--] Months: [-------] +32%
[--] Year: [-------] -62%
1-Year High: [------] on 2026-01-12
1-Year Low: [--] on 2025-09-07

Engagements by network (24h): TikTok: [--] X: [---] Reddit: [--] YouTube: [--]

Mentions: [--] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [---] -43%
1-Year High: [---] on 2026-01-11
1-Year Low: [--] on 2025-12-07

Mentions by network (24h): TikTok: [--] X: [--] Reddit: [--] YouTube: [--]

Creators: [--] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Zentalis Pharmaceuticals, LLC (ZNTL) in the last [--] hours which is up 50% from [--] in the previous [--] hours Daily Average: [--]
[--] Week: [--] -33%
1-Year High: [---] on 2026-01-10
1-Year Low: [--] on 2025-12-07

Sentiment: 100%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 100%
Daily Average: 89%
[--] Week: 100% no change
[--] Month: 100% +10%
[--] Months: 100% no change
[--] Year: 100% no change
1-Year High: 100% on 2025-02-19
1-Year Low: 33% on 2025-05-29

Most Supportive Themes:

  • Zentalis Pharmaceuticals Announces Positive Phase [--] Data for ZN-c3: (70%) Zentalis Pharmaceuticals LLC presented encouraging Phase [--] clinical trial results for their drug candidate ZN-c3, showing significant efficacy in treating certain types of cancer. The data has been met with enthusiasm from the oncology community and investors.
  • Zentalis Expands Clinical Trial Pipeline with New Cancer Targets: (30%) The company is broadening its research and development efforts, initiating new clinical trials for ZN-c3 and other promising compounds targeting various advanced cancers. This expansion signals a commitment to addressing unmet medical needs.

Most Critical Themes:

  • Regulatory Hurdles and Competition in Oncology Drug Development: (60%) Zentalis Pharmaceuticals faces a competitive landscape and stringent regulatory pathways for new cancer therapies. The success of ZN-c3 will depend on navigating these challenges effectively and demonstrating a clear advantage over existing treatments.
  • Manufacturing Scale-Up and Supply Chain Considerations for ZN-c3: (40%) Ensuring a robust and scalable manufacturing process for ZN-c3 is crucial for its eventual market availability. Potential supply chain disruptions or manufacturing complexities could impact the drug's timely delivery to patients.

Social Dominance: 0.00184%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00184%
Daily Average: 0.00465%
[--] Week: 0.0038% +0.0017%
[--] Month: 0.007% -0.003%
[--] Months: 0.007% +0.0048%
[--] Year: 0.007% -0.0005999999999999998%
1-Year High: 0.061% on 2026-01-11
1-Year Low: 0.0002% on 2025-10-04

Market Dominance: 0.0001733849341875062%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.0001733849341875062%
Daily Average: 0%
1-Year High: 0.00726% on 2026-01-13
1-Year Low: 0.00017% on 2026-02-18

Market Cap: $152,811,838

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $152,811,838
Daily Average: $173,392,086
[--] Week: $150,221,807 -5.70%
[--] Month: $152,811,838 -20%
1-Year High: $227,275,234 on 2026-01-14
1-Year Low: $143,099,222 on 2026-02-05

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing

Zentalis Pharmaceuticals, LLC (ZNTL)
/topic/zentalis-pharmaceuticals-llc